Anavex Life Sciences Corp (AVXL)

[frrol]

TLDs can be limited for legitimate reasons, so why only some components of the PDD trial's CDR battery endpoint were released while others were not with no explanation is puzzling. Biotechs often and unnecessarily cherry pick and open themselves up to criticism. For Rett, the shift to AUC was adequately explained, but not properly handled. Throw in the conspicuous yet unaddressed lack of dose effect and, again, the company opens itself up to more questions. (Perhaps dose effect will be seen in the OLE results, though it is unclear if we'll get them for Rett.)

Nevertheless the potential signal is there, and our clinical programs are proceeding. Watch for the PDD OLE and AD phase 2/3 results.